RESEARCH ARTICLE Asian Journal of Dairy and Food Research, Volume 45 Issue 2: 227-233 (April 2026)

Lactic Acid Bacteria Isolated from Dairy Products Exhibit Probiotic Potential and Anticancer Activity

Ashwini Jadhav[1,2], Nidhi Sharma[1], Samradni Pingale[1,2], Apoorva Parimoo[1], Ruchika Kaul-Ghanekar[1,2,3]

10.18805/ajdfr.DR-2417

ABSTRACT

Background: In this study, we aimed to isolate bacterial strains from curd and buttermilk samples to explore their probiotic and anticancer potential.

Methods: We isolated five bacterial strains from curd and buttermilk samples sourced from various origins. Identification was performed using 16S rRNA gene sequencing. Probiotic potential was assessed through tolerance tests to low pH and bile salt concentration. Antimicrobial and co-aggregation activities were evaluated for selected strains. Cell-free supernatants (CFS) were tested for anticancer activity against cervical and breast cancer cell lines.

Result: Among the isolated strains, *Limosi lactobacillus* fermentum K-2, *L. fermentum* D-1, Weissella confusa U-2, *Lactobacillus delbrueckii* Br and *L. delbrueckii* M-2 were identified by 16S rRNA gene sequencing. Strains K-2, D-1 and U-2 exhibited probiotic potential with high tolerance (>90%) to low pH (3.0) and bile salt (0.3%) concentration. Strain K-2 showed efficient antimicrobial and co-aggregation activity against clinical pathogens. Additionally, CFS of the selected LAB strains displayed anticancer activity against cervical and breast cancer cell lines. The findings suggest that the isolated dairy probiotic has potential utility in functional food and therapeutic applications.

Key words: Anticancer, Auto-aggregation, Co-aggregation, *Limosi lactobacillus*, Probiotic.

INTRODUCTION

Breast and cervical cancers are the major causes of cancer incidence and mortality among Indian women (Sathishkumar *et al.*, 2021; Kulothungan *et al.*, 2024). Among molecular subtypes of breast cancer, triple-negative [ER-/PR-/HER2-] breast cancer (TNBC) is the most prevalent (Arpita *et al.*, 2021), followed by luminal A [ER^+/PR^+/HER2-] (Jonnada *et al.,* 2021) subtypes in the Indian women. In India, infection with human papillomavirus (HPV) types 16 and 18 account for nearly 76.7% of cervical cancer cases (Kaarthigeyan, 2012; Ramamoorthy *et al.,* 2022).

Cancer patients undertaking chemotherapy or radiation therapy often experience side effects such as nausea, vomiting, diarrhoea and loss of appetite, leading to lower dietary intake and weight loss, drug resistance and recurrence. Thus, there is an urgent need to explore adjunct therapeutic approaches for effectively managing breast and cervical cancer.

Recently, various studies have shown that intake of dietary supplements, probiotics and fermented food products, could overcome chemo- and radiation therapy-associated side effects and reduce cancer development (Wei *et al.*, 2018; Legesse Bedada *et al.*, 2020). Lactic acid bacteria (LAB) from the genera Lactobacillus, Bifidobacterium, Pediococcus and Streptococcus are generally considered as safe (GRAS) probiotics due to their non-pathogenic nature and beneficial effects (FAO/WHO, 2001). Fermented dairy products have been reported to be good sources of LAB (Sugandhi, 2018) with anticancer activity against cervical and breast cancer (Ayyash *et al.,* 2018; Krishnaprabha *et al.*, 2024; Asoudeh-Fard *et al.*, 2024).

In the present study, we have isolated and identified five different LABs from commercial dairy products such as curd and buttermilk and characterized them for their *in vitro* probiotic potential. Out of all the tested microorganisms, *L. fermentum* K-2, *L. fermentum* D-1 and Weissella confusa U-2 showed significant anticancer activity against HPV 16 (SiHa) and HPV 18 (HeLa) positive cervical and triple

[1]Interactive Research School for Health Affairs, Bharati Vidyapeeth Deemed University, Pune-411 043, Maharashtra, India.
[2]Cancer Research Lab, Symbiosis School of Biological Sciences, Symbiosis International (Deemed University), Pune-412 115, Maharashtra, India.
[3]Symbiosis Centre for Research and Innovation, Symbiosis International (Deemed University), Pune-412 115, Maharashtra, India.

Corresponding Author: Ashwini Jadhav, Interactive Research School for Health Affairs, Bharati Vidyapeeth Deemed University, Pune-411 043, Maharashtra, India.
Email: ashwinijadhav5613@gmail.com

How to cite this article: Jadhav, A., Sharma, N., Pingale, S., Parimoo, A. and Kaul-Ghanekar, R. (2026). Lactic Acid Bacteria Isolated from Dairy Products Exhibit Probiotic Potential and Anticancer Activity. *Asian Journal of Dairy and Food Research*. **45(2):** 227-233. doi: 10.18805/ajdfr.DR-2417.

Submitted: 05-11-2025 **Accepted:** 13-01-2026 **Online:** 29-01-2026

negative ($ER^-/PR^-/Her2^-$) (MDAMB231) and $ER^+/PR^+/Her2^-$ (MCF-7) breast cancer cell lines. Among these, *L. fermentum* K-2 was found to be the best probiotic with promising anticancer activity.

MATERIALS AND METHODS

Samples, media and bacterial strains

Five samples of curd and five of buttermilk were collected from different areas of Pune, Maharashtra. The samples collected in sterile glass containers, either used immediately for microbial isolation or kept at 4°C until further use. All the microbial growth media were purchased from HiMedia, Mumbai, India. Clinical pathogens, *Staphylococcus aureus* 2043 and *Staphylococcus epidermidis* 2044, *Pseudomonas aeruginosa* 2081 and *Escherichia coli* 2412 were procured from National Centre for Microbial Resource (NCMR), National Centre for Cell Science (NCCS) Pune.

Cultivation, isolation and maintenance of bacteria

Curd and buttermilk samples were diluted in sterile phosphate buffered saline (PBS, pH 7). For isolating lactic acid bacteria, aliquots from dilution were spread onto the De Man, Rogosa and Sharpe **(**MRS) agar (pH 6.5) plates and incubated at 37°C for 48 h using Gas Pak system. The purified isolates with rod shape cells, Gram positive in nature and with catalase negative test was selected and preserved in 25% (v/v) glycerol at -80°C or subjected for further identification using 16S rRNA gene sequencing from commercial services of NCMR, Pune. The clinical pathogens were also maintained and propagated in nutrient media at 37°C for 24 h. The bacterial growth was analysed as optical density (OD) at 600 nm using microplate reader (Epoch, BioTek Instruments, Inc, USA) and determined by colony count method.

In vitro confirmation of pathogenicity and probiotic traits

Isolates were characterized for probiotic traits such as non-pathogenicity, acid and bile tolerance study, antibacterial and aggregation activities. Non-pathogenicity of the selected LAB using hemolysis assay was performed as described previously (Kamble *et al.*, 2022). The ability of the strains to survive under gastric and intestinal conditions was evaluated by *in vitro* acid and bile tolerance studies (Kamble *et al.*, 2022).

The antibacterial property of the selected isolates was evaluated by agar well diffusion method (Khalil *et al.*, 2018). Cell-free supernatant (CFS) was prepared as described previously (Kamble *et al.,* 2022). 150 µl CFS was loaded into the wells (8 mm diameter). The plates were kept in the refrigerator (4°C) for CFS diffusion into agar and incubated at 35°C for 24 h. Antibacterial activity was determined by measuring the diameter of the zone of inhibition (mm) around the well. All the grown cultures were centrifuged at 3000 rpm for 5 min for the auto-aggregation assay. The resultant cell pellets were washed and resuspended in PBS (pH 7.0) buffer to reach OD_{600nm} of 0.5±0.1. Then, 2 ml of each bacterial suspension was mixed for 10s and incubated at 35°C without agitation. An aliquot was taken from the top of the suspensions after 0 and 5 h of incubation and measured absorbance at 600 nm. The auto-aggregation percentage was calculated as described in using following equation:

$$\% \text{ autoaggregation: } 1 - \frac{OD_t}{OD_0} \times 100$$

Where,

OD_0 = Represents the absorbance of the mixture at 0 h.

OD_t = The absorbance of the mixture at 5 h.

Co-aggregation between selected probiotic strains and pathogens was carried out by the same method by only mixing the different strains in the ratio of 1:1. Control tubes containing 2 ml of each bacterial cell suspension alone were also made. The percentage of co-aggregation was calculated using the following equation (Janković *et al.*, 2012):

$$\% \text{ co-aggregation} = \frac{[(OD_1+OD_2)/2]-OD_3/(OD_1+OD_2)}{2} \times 100$$

Where,

OD_1 and OD_2 = Optical densities of LAB and pathogen alone at 5 h, respectively.

OD_3 = Optical density of suspension of bacterial and pathogenic culture at 5 h.

Cell culture and cell viability

The human cervical (HeLa and SiHa) cancer cell lines were obtained from the National Centre for Cell Science (NCCS), Pune, Maharashtra, India. Breast (MCF-7 and MDA-MB231) cancer cell lines were procured from American Type Culture Collection (ATCC, Manassas, USA). The cells were grown in Dulbecco's Modified Eagle Medium (DMEM) with 10% Fetal Bovine Serum (FBS) supplemented with 2 mM L-glutamine and antibiotics (100 U/ml penicillin and streptomycin). The cells were incubated in a humidified 5% CO_2 incubator at 37°C.

The effect of different concentrations (0, 4, 8, 16, 32 mg/ml) of lyophilized CFS of *L. fermentum* K-2, *L. fermentum* D-1 and *W. confusa* U-2 on the cell viability (at density of 1×10^4 cells/ml) of Hela, SiHa, MCF-7 and MDA-MB231 cells was determined by (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (MTT) assay in 96-well plates as previously described (Deshpande *et al.*, 2016).

Statistical analysis

The data were presented as mean ± standard deviation (SD) and analyzed for statistical significance by two-way analysis of variance (ANOVA) using Tukey's multiple comparisons test. All the statistical analyses were performed by using Graph Pad Prism version 9 (GraphPad, San Diego, USA).

RESULTS AND DISCUSSION

Twenty-one bacterial isolates from different curd and buttermilk samples were isolated. All the isolates were

studied for their colony and cell morphology characteristics and catalase activity. A total of 5 isolates (Br, D-1, K-2, M-2 and U-2) showing *Lactobacillus*-like morphology such as rods, Gram positive and catalase negative activity, were subjected to 16S rRNA sequencing. The sequencing data (Table S1) showed that these five isolates belonged to three different genera that includes *Limosi lactobacillus* (K-2 and D-1), *Lactobacillus* (Br and M-2) and *Weissella* (U-2). The sequences of the strains, *L. fermentum* K-2, *L. fermentum* D-1, W. confusa U-2, *L. delbrueckii* Br and L. delbrueckii M-2 have been deposited in GenBank (https://www.ncbi.nlm.nih.gov/) with accession numbers MZ066814, MZ066815, MZ066816, MZ066817 and MT093470, respectively.

The selected strains did not show any hemolytic zone around the colonies, revealing their γ-hemolytic activity and, thus, non-pathogenic nature.

In the acid tolerance study, among all the strains, W. confusa U-2 showed significantly ($p<0.0001$) higher viable cell count (9.25±0.03 log CFU/ml; SR: 97.99%) at acidic conditions, followed by *L. fermentum* K-2 (8.89±0.05 log CFU/ml; SR: 94.47%) and *L. fermentum* D-1 (8.88±0.06 log CFU/ml; SR: 95.28%) (Table 1). In the bile tolerance study, at 0.3% bile salt concentration, among all the strains tested, *W. confusa* U-2 showed a significantly higher viable count (8.96±0.04 log CFU/ml; SR: 94.92%) and higher bile salt tolerance ($p<0.0001$) (Table 1). One study has reported 86.20 and 84.99% survival rates at pH 3.0 and 0.3% bile concentration, respectively, for *L. fermentum* DUR 18 isolated from fermented food (Khalil *et al.*, 2018). W. confusa PUFSTMO55 isolated from idli batter showed good survival under acidic and bile conditions (Sharma *et al.*, 2018). The present study showed that *L. fermentum* K-2, *L. fermentum* D-1 and *W. confusa* U-2, displayed excellent acidic and bile tolerance properties and thus could be good candidates for future clinical use.

The antibacterial activity of CFS of K-2, D-1, U-2, Br and M-2 was assessed based upon their zone of inhibition (ZOI) against four clinical pathogens (Table 2). Overall, The CFS of *L. fermentum* K-2 exhibited higher antibacterial activity against *S. aureus* 2043, S. epidermidis 2044, *E. coli* 2412 and P. aeruginosa 2081 (Table 2). Similar results have been reported for CFS from *L. fermentum* 89-1 (Dallal *et al.*, 2016) against *P. aeruginosa*. CFS from the curd isolates, *Lactobacillus* casei, *L. delbrueckii*, *L. fermentum*, *L. plantarum* and *L. pentosus*, were reported to exhibit weak activity against *P. aeruginosa*, without inhibiting *S. aureus* and *E. coli* (Sharma *et al.*, 2017). On the other hand, *Weissella confusa* DD_A7 and *W. confusa* K3 isolated from kimchi and dairy products, respectively, exhibited antibacterial activity against *E. coli* (El-Mekkawy *et al.*, 2023; Krishnan *et al.*, 2019). The antimicrobial activity of each probiotic is strain-specific and thus it is an essential criterion for selecting the best probiotic. Probiotic bacteria

Supplementary Table 1: Taxonomic identity and sources of probiotic strain cultures.

Isolate	Source	Closest relative	Similarity (%)	Accession no. for deposited culture*
K-2	Buttermilk K	*Limosilactobacillus fermentum* CECT562^T	99.8	MCC 4683
D-1	Curd D	*Limosilactobacillus fermentum* CECT562^T	99.9	MCC 4682
U-2	Buttermilk U	*Weissella confusa* JCM1093^T	100	MCC 4684
Br	Curd Br	*Lactobacillus delbrueckii* ZN7a-9^T	99.8	MCC 4689
M-2	Curd M	*Lactobacillus delbrueckii* JCM15610^T	100	MCC 4688

Buttermilk sample K (BK) and sample U (BU) represent buttermilk obtained from different sources; Curd sample D (CD), Br (CBr) and M (CM) represent curd obtained from different sources. *All the identified cultures have been deposited at the National Centre for Microbial Resource (NCMR), Pune, Maharashtra, India.

Table 1: pH and bile salt tolerance of the identified strains.

Strains	pH Tolerance		Bile salt tolerance(0.3%, w/v)		
	Log CFU/ ml0 h	Log CFU/ ml3 h	Survival rate (SR) (%)	Log CFU/ ml3 h	Survival rate (SR) (%)
L. fermentum K-2	9.41±0.04^A	8.89±0.05^A	94.47	8.79±0.08^A	93.41
L. fermentum D-1	9.32±0.02^{AaB}	8.88±0.06^{AaB}	95.28	8.63±0.06^{AcB}	92.60
W. confusa U-2	9.44±0.04^{AaBbC}	9.25±0.03^{AdBdC}	97.99	8.96±0.04^{AdBdC}	94.92
L. delbrueckii Br	9.22±0.02^{AdBaCcD}	7.61±0.19^{AdBdCdD}	82.54	7.30±0.0^{AdBdCdD}	79.18
L. delbrueckii M-2	9.13±0.04^{AdBdCcDa}	7.40±0.15^{AdBdCdDd}	81.05	7.30±0.0^{AdBdCdDa}	79.96

The data has been presented as mean±SD of three independent experiments, each performed in triplicates. The data was analyzed for statistical significance by two-way analysis of variance (ANOVA) with multiple comparisons followed by Tukey's test. Aap>0.05, Acp<0.001 and Adp<0.0001 compared to A (*L. fermentum* K-2); Bap>0.05, Bbp<0.05 and Bdp<0.0001 compared to B (*L. fermentum* D-1); Ccp<0.001 and Cdp<0.0001 compared to C (*W. confusa* U-2); Dap<0.0001 and Ddp<0.0001 compared to D (*L. delbrueckii* Br).

are known to secrete different antimicrobial substances or metabolites such as short-chain fatty acids (lactic, acetic or butyric acids), hydrogen peroxide, diacetyl, bacteriocins, peptides (Sharma *et al.*, 2017), hygroline, taraxinic acid glucosyl ester, avocadyne 2-acetate, hydroxypentadecanedioic acid (Rocchetti *et al.*, 2020; Kamble *et al.*, 2022).

The auto-aggregation assay was examined for the selected three probiotic strains on the basis of their sedimentation characteristics. *L. fermentum* K-2 exhibited significantly higher auto-aggregation (70.23±1.92%; p<0.0001), followed by *L. fermentum* D-1 (47.09±1.10%) and W. confusa U-2 (36.68±1.10%) (Table S2). Studies have reported 30% auto-aggregation for *L. fermentum* (Padmavathi *et al.*, 2018) and 70.19% for *L. fermentum* TCUESC01 (Melo *et al.*, 2017). The co-aggregation studies indicated that *L. fermentum* K-2 exhibited higher co-aggregation (58.75±1.42%; p<0.0001) with *P. aeruginosa* compared to either *L. fermentum* D-1 (40.96±1.55%; p<0.0001) or *W. confusa* U-2 (20.37±1.46%; p<0.0001) (Table S2). *L. fermentum* has been previously reported to show good co-aggregation with *P. aeruginosa* (Batoni *et al*., 2023).

In the present study, we have evaluated the anticancer activity of CFS from *L. fermentum* K-2, *L. fermentum* D-1 and *W. confusa* U-2 against HPV 18 (HeLa) and HPV 16 (SiHa) positive cervical cancer cell lines; and ER^+/PR^+/Her2 (MCF-7) and $ER^-/PR^-/Her2^-$ (MDA-MB-231) breast cancer cell lines. The cells were treated with lyophilized CFSs at different concentrations (0-32 mg/ml) for 24 h. At higher dose of 32 mg/ml, CFS of K-2 and D-1 significantly (p<0.0001) reduced the viability of the tested cell lines (Fig 1 A-D). CFS of U-2, at a dose of 32 mg/ml, significantly (p<0.0001) reduced the viability of HeLa, SiHa and MDA-MB231 cancer cell lines, except for MCF-7.

Substantial data is available on the anticancer properties of probiotic strains, *L. fermentum* and *W. confusa*, against colorectal cancer (Arian *et al.*, 2019; Du *et al*., 2023; Liu *et al.*, 2023) with very few studies against breast and cervical cancer cells. For instance, exopolysaccharide (EPS), isolated from *L. fermentum* DSM 20049, reduced the viability of MCF-7 cells with IC_{50} of 22.97 mg/ml (Khalil *et al.,* 2022). The intracellular total protein of *L. fermentum* K81, *L. fermentum* K85 exhibited 69.84±0.73 and 63.47±2.90% cytotoxicity against HeLa, respectively (Purkayastha *et al*., 2020). Camel milk-derived probiotic strains, *L. plantarum*, *L. acidophilus*, *L. reuteri* and *L. lactis*, significantly inhibited the proliferation of MCF7 and HeLa (Ayyash *et al.,* 2018). Lactobacillus species, isolated from mulberry silage (Shokryazdan *et al*., 2017), has shown anticancer activity against MDA-MB-231. Anticancer and apoptotic activity of conditioned medium from *L. fermentum* Ab.RS22, isolated from dairy products, was reported against HeLa *via* upregulation of PTEN and downregulation of AKT genes (Asoudeh-Fard *et al.,* 2024). The anticancer activity of cytoplasmic and cell wall extracts of commercial *L. delbrueckii* capsules have been reported against SiHa via the expression of apoptotic genes BCL2, caspase-3, caspase-9 and BAX (Bi *et al.*, 2023). EPS-5, isolated from *L. delbrueckii* DSM 20081, has shown anticancer activity against MCF-7 with IC_{50} of 7.91 mg/ml (Khalil *et al.*, 2022).

Table 2: Antibacterial potential of selected probiotics against pathogens.


Probiotic strains	Zone of inhibition (mm)			
	S. aureus	*S. epidermidis*	*E. coli*	*P. aeruginosa*
L. fermentum K-2	16.78 ± 0.97^{A}	15.78 ± 0.67^{A}	18.00 ± 0.87^{A}	20.33 ± 0.50^{A}
L. fermentum D-1	15.78 ± 0.44^{AbB}	13.00 ± 0.87^{Ac}	14.78 ± 0.83^{AcB}	17.78 ± 0.83^{AcB}
W. confusa U-2	10.33 ± 1.12^{AcBc}	NA	13.33 ± 1.00^{AcBc}	17.00 ± 0.71^{AcBaC}
L. delbrueckii Br	NA	NA	NA	15.00 ± 0.50^{AcBcCcD}
L. delbrueckii M-2	NA	NA	NA	$10..00\pm0.71^{AcBcCcDc}$

NA indicates no activity. The data have been presented as mean±SD of three independent experiments, each performed in triplicates. The data was analyzed for statistical significance by two-way analysis of variance (ANOVA) with multiple comparisons followed by Tukey's test. Abp<0.05 and Acp<0.0001 compared to A (*L. fermentum* K-2); Bap>0.05 Bcp<0.0001 compared to B (*L. fermentum* D-1); Ccp<0.0001 compared to C (*W. confusa* U-2); Dcp<0.0001 compared to D (*L. delbrueckii* Br).

Supplementary Table 2: Auto-aggregation and co-aggregation properties of the selected probiotic strains.

Probiotic strains	Auto-aggregation (%)	Co-aggregation (%)			
		S. aureus	*S. epidermidis*	*P. aeruginosa*	*E. coli*
L. fermentum K-2	70.23 ± 1.92^{A}	38.45 ± 1.07^{A}	31.93 ± 2.00^{A}	58.75 ± 1.42^{A}	47.64 ± 1.75^{A}
L. fermentum D-1	47.09 ± 1.10^{AcB}	36.96 ± 0.64^{AaB}	31.82 ± 0.75^{AaB}	40.96 ± 1.55^{AcB}	43.56 ± 1.98^{AbB}
W. confusa U-2	36.68 ± 1.10^{AcBc}	NA	NA	20.37 ± 1.46^{AcBc}	4.60 ± 1.98^{AcBc}

NA indicates no activity. The data have been presented as mean±SD of three independent experiments, each performed in triplicates. The data was analyzed for statistical significance by two-way analysis of variance (ANOVA) with multiple comparisons followed by Tukey's test. Aa*p*>0.05, Ab*p*<0.005 and Ac*p*<0.0001 compared to A (*L. fermentum* K-2); Bc*p*>0.0001 compared to B (*L. fermentum* D-1).



The effect of CFS from K-2, D-1 and U-2 was tested on the viability of A) HeLa, B) SiHa, C) MCF-7 and D) MDA-MB 231) by MTT assay. Data has been represented as Mean+SD; n=8. p>0.05 considered to be non-significant and ***(p<0.0001) indicate statistically significant difference.

Fig 1: Cell-free supernatant (CFS) of probiotic strains reduced the viability of cervical and breast cancer cell lines.

Probiotics have been shown to exhibit anticancer activity by a) secreting short-chain fatty acids (SCFAs) such as acetate, butyrate, propionate (Thirabunyanon and Hongwittayakorn, 2013) that lower the vaginal pH to 4.5 and prevent the growth of carcinogen-producing pathogens and increase mucosal viscosity of vaginal epithelium, thereby preventing the virus entry (Sharifian *et al.*, 2023b) binding of probiotics to genotoxic carcinogens (Legesse Bedada *et al.,* 2020c) producing anti-tumor compounds such as bacteriocin (Chuah *et al.,* 2019; Saeed *et al.,* 2025), peptidoglycan, exopolysaccharide (Khalil *et al.*, 2022), acetamide, thiocyanic acid (Sharma and Shukla, 2020) that inhibit cell proliferation; d) inducing apoptosis (Hadid *et al*., 2025) through upregulation of pro-apoptosis proteins (Bi *et al.*, 2023e) induction of cell cycle arrest by upregulating p21, p53 (Liu *et al.*, 2023f) activating immune system (Kim *et al.*, 2021) and in effect exerting anti-proliferating activity. The overall data suggests that the anticancer activity of the CFS from the selected probiotic strains could be due to the secretion of various bioactive metabolites.

The present study has shown that dairy probiotics with anticancer potential could be explored as adjuncts to conventional therapies against cervical and breast cancer.

CONCLUSION

The isolated LAB from dairy samples exhibited potential anticancer activity against breast and cervical cancer cells. Such LAB strains could be proposed as functional food supplements to be used as adjuncts during cancer therapies. However, elaborate studies are warranted to understand the underlying mechanisms of these probiotics and their role in mitigation of the risk of cancer. Further studies, including therapeutic efficacy and adverse reactions of probiotics such as bacteremia, gastrointestinal side effects, antibiotic resistance and abnormal stimulation of the immune system in cancer patients, need to be carefully evaluated in the future.

ACKNOWLEDGEMENT

We thank Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth (deemed to be) University, Pune for facilitating this study.

Funding information

There is no funding information.

Data and materials availability

The obtained data will be available upon request.

Ethics approval

This study does not involve any animals or human participants.

Conflict of interest

The authors declare that there are no conflicts of interest.

REFERENCES

Arian, S., Kaboosi, H., Heshmatipour, Z., Khazaei Koohpar, Z. and Peyravii, F. (2019). Anti-proliferative effects of two new Lactobacillus strains of human origin on Caco-2 cell line. *Iranian Red Crescent Medical Journal.* **221(3):** e84683. https://doi.org/10.5812/ircmj.84683.

Arpita, J., Priyanka, G. and Ranjana, S. (2021). A study of molecular subtypes of carcinoma breast by immunohistochemistry at tertiary care center, Jaipur. *Asia Pacific Journal of Cancer Biology*. **7(3):** 219-223. https://doi.org/10.31557/apjcb.2022.7.3.219-223.

Asoudeh-Fard, A., Salehi, M., Ilghari, D., Parsaei, A., Heydarian, P. and Piri, H. (2024). Isolated *Lactobacillus fermentum* Ab. RS22 from traditional dairy products inhibits HeLa cervical cancer cell proliferation and modulates apoptosis by the PTEN-Akt pathway. *Iranian Journal of Basic Medical Sciences*. **27(4):** 447-452. https://doi.org/10.22038/IJBMS.2023.72825.15846.

Ayyash, M., Al-Nuaimi, A.K., Al-Mahadin, S. and Liu, S.Q. (2018). *In vitro* investigation of anticancer and ACE-inhibiting activity, α-amylase and α-glucosidase inhibition and antioxidant activity of camel milk fermented with camel milk probiotic: A comparative study with fermented bovine milk. *Food Chemistry.* **239:** 588-597. https://doi.org/10.1016/j.foodchem.2017.06.149.

Batoni, G., Catelli, E., Kaya, E., Pompilio, A., Bianchi, M., Ghelardi, E., Di Bonaventura, G., Esin, S. and Maisetta, G. (2023). Antibacterial and antibiofilm effects of Lactobacilli strains against clinical isolates of *Pseudomonas aeruginosa* under conditions relevant to cystic fibrosis. *Antibiotics*. **12(7):** 1158. https://doi.org/10.3390/antibiotics12071158.

Bi, Z., Wang, Q., Yang, T., Liu, Y., Yuan, J., Li, L. and Guo, Y. (2023). Effect of *Lactobacillus delbrueckii* subsp. lactis on vaginal radiotherapy for gynecological cancer. *Scientific Reports*. **13(1):** 1-15. https://doi.org/10.1038/s41598-023-37241-7.

Chuah, L.O., Foo, H.L., Loh, T.C., Mohammed Alitheen, N.B., Yeap, S.K., Abdul Mutalib, N.E., Abdul Rahim, R. and Yusoff, K. (2019). Postbiotic metabolites produced by *Lactobacillus plantarum* strains exert selective cytotoxicity effects on cancer cells. *BMC Complement Altern Med*. **2:** 1-12. https://doi.org/10.1186/s12906-019-2528-2.

Dallal, M., Davoodabadi, A., Abdi, M., Hajiabdolbaghi, M., Yazdi, M. and Douraghi, M. (2016). Inhibitory effect of *Lactobacillus plantarum* and *Lb. fermentum* isolated from the faeces of healthy infants against nonfermentative bacteria causing nosocomial infections. *New Microbes and New Infections*. **15:** 9-13. https://doi.org/10.1016/j.nmni.2016.09.003.

Deshpande, R., Mansara, P. and Kaul-Ghanekar, R. (2016). Alpha-linolenic acid regulates Cox2/VEGF/MAP kinase pathway and decreases the expression of HPV oncoproteins E6/E7 through restoration of p53 and Rb expression in human cervical cancer cell lines. *Tumor Biology.* **37(3):** 3295-3305. https://doi.org/10.1007/s13277-015-4170-z.

Du, Y., Liu, L., Yan, W., Li, Y., Li, Y., Cui, K., Yu, P., Gu, Z., Zhang, W., Feng, J., Li, Z., Tang, H., Du, Y. and Zhao, H. (2023). The anticancer mechanisms of exopolysaccharide from *Weissella cibaria* D-2 on colorectal cancer *via* apoptosis induction. *Scientific Reports*. **13(1):** 1-14. https://doi.org/10.1038/s41598-023-47943-7.

El-Mekkawy, R.M., Hamour, N.E., Hassanein, W.A. and Allam, A.A. (2023). Evaluation of the antibacterial activity of *Weissella confusa* K3 cell-free supernatant against extended-spectrum βeta lactamase (ESBL) producing uropathogenic Escherichia coli U60. *Saudi Journal of Biological Sciences*. **30(4):** 103595. https://doi.org/10.1016/j.sjbs.2023.103595.

FAO/WHO, Probiotic in Food. Health and Nutritional Properties and Guidelines for Evaluation, 2001, http://www.fao.org/3/a a0512e.pdf.

Hadid, M.A., Hasan, A.F., Al-Halbosiy, M.F., Al-Maliki, N.S., Al-Shaibani, A.B., Mohammed, S.A. and El-Wahsh, H.M. (2025). Cytotoxicity and apoptosis induction of *Lactobacillus acidophilus* cell-free supernatant against human colon carcinoma cell line. *Agricultural Reviews*. pp. 1-8. doi: 10.18805/ag.RF-383.

Janković, T., Frece, J., Abram, M. and Gobin, I. (2012). Aggregation ability of potential probiotic *Lactobacillus plantarum* strains. *International Journal of Sanitary Engineering Research*. **6(1):** 19-24. https://doi.org/10.1016/j.nmni.2016.09.003.

Jonnada, P.K., Sushma, C., Karyampudi, M. and Dharanikota, A. (2021). Prevalence of molecular subtypes of breast cancer in india: A systematic review and meta-analysis. *Indian Journal of Surgical Oncology*. **12:** 152-163. https://doi.org/10.1007/s13193-020-01253-w

Kaarthigeyan, K. (2012). Cervical cancer in India and HPV vaccination. *Indian Journal of Medical and Paediatric Oncology.* **33(1):** 7-12. https://doi.org/10.4103/0971-5851.96961.

Kamble, A., Naik, S., Talathi, M., Jadhav, D., Pingale, S. and Kaul-Ghanekar, R. (2022). Cervicovaginal microbiota isolated from healthy women exhibit probiotic properties and antimicrobial activity against pathogens isolated from cervical cancer patients. *Archives of Microbiology*. **204(8):** 491. https://doi.org/10.1007/s00203-022-03103-5.

Khalil, E.S., Manap, M.Y.A., Mustafa, S., Alhelli, A.M. and Shokryazdan, P. (2018). Probiotic properties of exopolysaccharide-producing lactobacillus strains isolated from tempoyak. *Molecules*. **23(2):** 1-20. https://doi.org/10.3390/molecules23020398.

Khalil, M.A., Sonbol, F.I., Al-Madboly, L.A., Aboshady, T.A., Alqurashi, A.S. and Ali, S.S. (2022). Exploring the therapeutic potentials of exopolysaccharides derived from lactic acid bacteria and bifidobacteria: antioxidant, antitumor and periodontal regeneration. *Frontiers in Microbiology*. **13:** 1-19. https://doi.org/10.3389/fmicb.2022.803688.

Kim, K.T., Yang, S.J. and Paik, H.D. (2021). Probiotic properties of novel probiotic *Levilactobacillus brevis* KU15147 isolated from radish kimchi and its antioxidant and immune-enhancing activities. *Food Science and Biotechnology*. **30(2):** 257-265. https://doi.org/10.1007/s10068-020-00853-0.

Krishnaprabha, V., Ramakrishnan, L., Vijayaraghavan, R. and Unnikrishnan, G. (2024). Physiochemical properties, anti-pathogenic and anti-tumour activity of whey based probiotic Muskmelon health beverage. *Asian Journal of Dairy and Food Research*. **43(1):** 46-52. doi: 10.18805/ajdfr.DR-2018.

Krishnan, M., Dey, D.K., Sharma, C. and Kang, S.C. (2019). Antibacterial activity of Weissella confusa by disc diffusion method. *Bangladesh Journal of Pharmacology*. **14(3):** 117-122. https://doi.org/10.3329/bjp.v14i3.41545.

Kulothungan, V., Ramamoorthy, T., Sathishkumar, K., Mohan, R., Tomy, N., Miller, G.J. and Mathur, P. (2024). Burden of female breast cancer in India: Estimates of YLDs, YLLs and DALYs at national and subnational levels based on the national cancer registry programme. *Breast Cancer Research and Treatment*. **205(2):** 323-332. https://doi.org/10.1007/s10549-024-07264-3.

Legesse Bedada, T., Feto, T.K., Awoke, K.S., Garedew, A.D., Yifat, F.T. and Birri, D.J. (2020). Probiotics for cancer alternative prevention and treatment. *Biomedicine and Pharmacotherapy*. **129:** 110409. https://doi.org/10.1016/j.biopha.2020.110 409.

Liu, L., Du, Y., Du, Y., Yan, W., Li, Y., Cui, K., Li, Z., Yu, P., Zhang, W., Feng, J., Ma, W. and Zhao, H. (2023). Exopolysaccharide from *Weissella confusa* J4-1 inhibits colorectal cancer *via* induction of cell cycle arrest. *International Journal of Biological Macromolecules*. **253:** 127625. https://doi.org/10.1016/j.ijbiomac.2023.127625.

Melo, T.A., Dos Santos, T.F., Pereira, L.R., Passos, H.M., Rezende, R.P. and Romano, C.C. (2017). Functional profile evaluation of *Lactobacillus fermentum* TCUESC01: A new potential probiotic strain isolated during cocoa fermentation. *BioMed Research International*. pp. 1-7. https://doi.org/10.1155/2017/5165916.

Padmavathi, T., Bhargavi, R., Priyanka, P.R., Niranjan, N.R. and Pavitra, P.V. (2018). Screening of potential probiotic lactic acid bacteria and production of amylase and its partial purification. *Journal of Genetic Engineering and Biotechnology*. **16(2):** 357-362. https://doi.org/10.1016/j.jgeb.2018.03.005.

Purkayastha, S.D., Bhattacharya, M.K., Prasad, H.K., Bhattacharjee, M.J., De Mandal, S., Mathipi, V. and Kumar, N.S. (2020). Probiotic and cytotoxic potential of vaginal *Lactobacillus* isolated from healthy Northeast Indian women. *Journal of Pure and Applied Microbiology*. **14(1):** 205-214. https://doi.org/10.22207/JPAM.14.1.22.

Ramamoorthy, T., Sathishkumar, K., Das, P., Sudarshan, K.L. and Mathur, P. (2022). Epidemiology of human papillomavirus related cancers in India: Findings from the National Cancer Registry Programme. *Ecancermedical Science.* **16:** 1-14. https://doi.org/10.3332/ecancer.2022.1444.

Rocchetti, G., Bernardo, L., Pateiro, M., Barba, F.J., Munekata, P.E.S., Trevisan, M., Lorenzo, J.M. and Lucini, L. (2020). Impact of a Pitanga leaf extract to prevent lipid oxidation processes during shelf life of packaged pork burgers: An untargeted metabolomic approach. *Foods*. **9(11):** 1668. https://doi.org/10.3390/foods9111668.

Saeed, M.K., Yusra, M.B., Mohsin, Enas, O.Z. and Jawad, F.G. (2025). The antibacterial effectiveness of bacteriocin output *via Streptococcus thermophilus* versus viral pathogens and spores. *Agricultural Science Digest*. 1-8. doi: 10.18805/ag.DF-627.

Sathishkumar, K., Vinodh, N., Badwe, R.A., Deo, S.V.S., Manoharan, N., Malik, R., Panse, N. S., Ramesh, C., Shrivastava, A., Swaminathan, R., Vijay, C.R., Narasimhan, S., Chaturvedi, M. and Mathur, P. (2021). Trends in breast and cervical cancer in India under National Cancer Registry Programme: An age-period-cohort analysis. *Cancer Epidemiology*. **74:** 101982. https://doi.org/10.1016/j.canep.2021.101982.

Sharifian, K., Shoja, Z. and Jalilvand, S. (2023). The interplay between human papillomavirus and vaginal microbiota in cervical cancer development. *Virology Journal*. **20(1):** 73. https://doi.org/10.1186/s12985-023-02037-8.

Sharma, C., Singh, B.P., Thakur, N., Gulati, S., Gupta, S., Mishra, S.K. and Panwar, H. (2017). Antibacterial effects of *Lactobacillus* isolates of curd and human milk origin against food-borne and human pathogens. *3 Biotech*. **7(1).** https://doi.org/10.1007/s13205-016-0591-7.

Sharma, M. and Shukla, G. (2020). Administration of metabiotics extracted from probiotic *Lactobacillus rhamnosus* md 14 inhibit experimental colorectal carcinogenesis by targeting wnt/β-catenin pathway. *Frontiers in Oncology*. **10:** 1-14. https://doi.org/10.3389/fonc.2020.00746.

Sharma, S., Kandasamy, S., Kavitake, D. and Shetty, P.H. (2018). Probiotic characterization and antioxidant properties of *Weissella confusa* KR780676, isolated from an Indian fermented food. *Lwt*. **97:** 53-60. https://doi.org/10.1016/j.lwt.2018.06.033.

Shokryazdan, P., Jahromi, M.F., Bashokouh, F., Idrus, Z. and Liang, J.B. (2018). Antiproliferation effects and antioxidant activity of two new *Lactobacillus* strains. *Brazilian Journal of Food Technology*. **21:** e2016064. https://doi.org/10.1590/1981-6723.6416.

Sugandhi Priya, G. (2018). Probiotics conventional benefits and cautions in intake- A review. *Agricultural Reviews*. **39(3):** 251-254. doi: 10.18805/ag.R-1749.

Thirabunyanon, M. and Hongwittayakorn, P. (2013). Potential probiotic lactic acid bacteria of human origin induce antiproliferation of colon cancer cells *via* synergic actions in adhesion to cancer cells and short-chain fatty acid bioproduction. *Applied Biochemistry and Biotechnology*. **169(2):** 511-525. https://doi.org/10.1007/s12010-012-9995-y.

Wei, D., Heus, P., van de Wetering, F.T., van Tienhoven, G., Verleye, L. and Scholten, R.J.P.M. (2018). Probiotics for the prevention or treatment of chemotherapy- or radiotherapy-related diarrhoea in people with cancer. *Cochrane Database of Systematic Reviews*. **8:** CD008831 https://doi.org/10.1002/14651858.CD008831.pub3.